Portola

Jabil and KAV Sports Harness the Power of Engineered Materials to Produce Game-Changing Customized Bike Helmets

Retrieved on: 
Monday, March 20, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230320005419/en/
    Jabil teamed with KAV Sports on a custom material, available in different colors, to produce tailor-made, 3D-printed bike helmets.
  • “For consumers to experience the benefits of customization, we had to overcome limitations in materials and manufacturing.
  • To achieve that milestone, Jabil applied comprehensive innovations in materials formulation, compound development, materials systems integration, and ISO 9001 Quality Management System certification.
  • “We take a polymer science approach to developing additive materials,” said Matt Torosian, director, product management for additive manufacturing at Jabil.

Synthekine Expands Board of Directors, Management Team and Scientific Advisory Board with New Key Appointments

Retrieved on: 
Thursday, June 3, 2021

She previously served as CFO and CBO of Portola Pharmaceuticals until its acquisition by Alexion Pharmaceuticals in 2020.

Key Points: 
  • She previously served as CFO and CBO of Portola Pharmaceuticals until its acquisition by Alexion Pharmaceuticals in 2020.
  • Before this, Ms. Dier served as vice president of investor relations at Chiron Corporation from 2003 to 2006.
  • We also look forward to Tonis valuable contributions to our scientific advisory board, given his leadership in cancer immunotherapy.
  • Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious.

PACT Pharma Announces Planned Retirement of CEO Alex Franzusoff; Veteran Biotech Executive Scott Garland Named as Successor

Retrieved on: 
Friday, March 5, 2021

Mr. Garland assumes the CEO role effective today, succeeding Alex Franzusoff, Ph.D., who will be staying with the company through mid-year in an advisory role to support the transition.

Key Points: 
  • Mr. Garland assumes the CEO role effective today, succeeding Alex Franzusoff, Ph.D., who will be staying with the company through mid-year in an advisory role to support the transition.
  • Mr. Garland was formerly CEO of Portola Pharmaceuticals, which was acquired by Alexion in 2020 for $1.4 billion.
  • At Portola, he led the company through the commercial launch of Andrexxa, a novel reversal agent for factor Xa inhibitors.
  • "I am honored and privileged to join PACT and its world class team at this important moment in the company's growth," said Mr. Garland.

Ultragenyx Expands Leadership Team and Appoints Ernie Meyer as Chief Human Resources Officer

Retrieved on: 
Tuesday, September 1, 2020

In this newly created role, Mr. Meyer will lead all aspects of the Global Human Resources and Facilities operations.

Key Points: 
  • In this newly created role, Mr. Meyer will lead all aspects of the Global Human Resources and Facilities operations.
  • He will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyxs Chief Executive Officer, and will serve on the Executive Leadership Team.
  • Mr. Meyer joins Ultragenyx from Portola Pharmaceuticals, where he was Executive Vice President, Chief Human Resources Officer since 2018.
  • Before Portola, he spent more than 13 years at Celgene, most recently as Executive Vice President of Human Resources and Corporate Services.

Alexion Completes Acquisition of Portola

Retrieved on: 
Thursday, July 2, 2020

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA).

Key Points: 
  • Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA).
  • Alexion completed the acquisition through a tender offer and subsequent merger of Portola with Odyssey Merger Sub Inc., a wholly owned subsidiary of Alexion (Buyer).
  • Portola is now a wholly owned subsidiary of Alexion.
  • On July 2, 2020, Alexion completed its acquisition of Portola through the merger of Buyer with and into Portola without a vote of Portolas shareholders pursuant to Section 251(h) of the Delaware General Corporation Law.

Rigrodsky & Long, P.A. Files Class Action Suit Against Portola Pharmaceuticals, Inc.

Retrieved on: 
Thursday, June 18, 2020

The Complaint, which alleges violations of the Securities Exchange Act of 1934 against Portola, its Board of Directors (the Board), Alexion, and Merger Sub, is captioned Post v. Portola Pharmaceuticals, Inc., Case No.

Key Points: 
  • The Complaint, which alleges violations of the Securities Exchange Act of 1934 against Portola, its Board of Directors (the Board), Alexion, and Merger Sub, is captioned Post v. Portola Pharmaceuticals, Inc., Case No.
  • If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiffs counsel, Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A.
  • On May 5, 2020, Portola entered into an agreement and plan of merger (the Merger Agreement) with Alexion and Merger Sub.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, May 11, 2020

"While encouraging, the emergence of the COVID-19 pandemic impacted our revenue in March and the quarter due to three main factors.

Key Points: 
  • "While encouraging, the emergence of the COVID-19 pandemic impacted our revenue in March and the quarter due to three main factors.
  • As previously announced on May 5, 2020, Portola entered into a definitive merger agreement to be acquired by Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN).
  • Total global revenues for the first quarter of 2020 were$26.4 million compared with$22.2 millionfor the same period in 2019.
  • Research and development (R&D) expenses for the first quarter of 2020 were $26.1 million compared with $35.6 million for the same period in 2019.

Portola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast and Conference Call Following Agreement to be Acquired by Alexion

Retrieved on: 
Tuesday, May 5, 2020

SOUTH SAN FRANCISCO, Calif., May 5, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) (the "Company" or "Portola") today announced that it is cancelling its webcast and conference call to discuss the Company's financial results for the first quarter ended March 31, 2020 that was previously scheduled for Monday, May 11, 2020, at4:30 p.m.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 5, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) (the "Company" or "Portola") today announced that it is cancelling its webcast and conference call to discuss the Company's financial results for the first quarter ended March 31, 2020 that was previously scheduled for Monday, May 11, 2020, at4:30 p.m.
  • This cancellation is due to the announcement on May 5, 2020, that Portola has entered into a definitive merger agreement to be acquired by Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN).
  • Portola will issue a press release reporting its first quarter 2020 financial results on Monday, May 11, 2020.
  • Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.

Alexion to Acquire Portola

Retrieved on: 
Tuesday, May 5, 2020

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today that they have entered into a definitive merger agreement for Alexion to acquire Portola, a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders.

Key Points: 
  • Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today that they have entered into a definitive merger agreement for Alexion to acquire Portola, a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders.
  • The merger agreement has been unanimously approved by the boards of Alexion and Portola.
  • Following successful completion of the tender offer, Alexion will acquire all remaining shares not tendered in the offer at the same price of $18 per share through a merger.
  • Alexion and Portola disclaim any obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.

Portola Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 11, 2020

Retrieved on: 
Thursday, April 23, 2020

SOUTH SAN FRANCISCO, Calif., April 23, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended March 31, 2020, and provide a general business overview, onMonday, May 11, 2020, at4:30 p.m.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 23, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended March 31, 2020, and provide a general business overview, onMonday, May 11, 2020, at4:30 p.m.
  • The live conference call onMonday, May 11, 2020, at4:30 p.m.
  • ET, can be accessed by phone by calling (844) 452-6828 fromthe United StatesandCanadaor 1 (765) 507-2588 internationally and using the passcode 9579507.
  • Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.